To support this site, please make your purchases through my Amazon link.
Tuesday, December 21, 2004
Not a good week for the FDA
Yet another in a string of negative stories for the agency.
An Alzheimer's disease prevention trial was suspended after researchers said there were more heart attacks and strokes among patients taking naproxen, an over-the-counter pain reliever in use for 28 years and commonly known under the brand name Aleve.Link.
The study, involving some 2,500 patients, was to test whether naproxen or Celebrex, both pain relievers, could reduce the risk of Alzheimer's disease among healthy elderly patients who were at an increased risk of the disease.
Officials at the National Institutes of Health said the study was suspended after three years when it was found that patients taking naproxen had a 50 percent greater incidence of cardiovascular events — heart attack or stroke — than patients taking placebo.
To support this site, please make your DVD, music, book and electronics purchases through my Amazon link.